Title : Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.

Pub. Date : 2021 Oct

PMID : 34164713






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Mean levels of the serum cytokine bFGF increased (p = 0.008) after the bevacizumab-only lead-in and decreased back to baseline (p = 0.047) after addition of tivantinib. ARQ 197 fibroblast growth factor 2 Homo sapiens
2 Tivantinib reversed the upregulation of bFGF caused by bevacizumab, which has been considered a potential mechanism of resistance to therapies targeting the VEGF pathway. ARQ 197 fibroblast growth factor 2 Homo sapiens